OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
PAX$11.5659

Paxman AB (publ)

Medical Equipment, Supplies & DistributionVerified

Paxman AB (publ) has a market price of 11.56 SEK and a market capitalization of 269,040,688.96 SEK, indicating a moderate valuation in the healthcare equipment and supplies industry. The company's price-to-earnings ratio of 20.52 and price-to-book ratio of 1.98 suggest that investors are paying a premium for its earnings and book value. The enterprise value to EBITDA ratio of 38.65 and enterprise value to revenue ratio of 4.88 indicate that the company is valued at a high multiple of its earnings and revenue. In terms of profitability, Paxman AB (publ) has a return on equity of 9.63% and a return on assets of 7.13%, which are metrics that reflect the company's ability to generate profits from its equity and assets. The company's operating income of 7,405,000 SEK and net income of 13,108,000 SEK demonstrate its capacity to generate profits from its operations. However, these figures should be compared to the industry median to determine if they are above or below average. Paxman AB (publ) has a revenue of 58,620,000 SEK, and there is no specific information provided about its segments or geographic exposure. The company's revenue concentration is not detailed, but it is important to consider the potential risks associated with a lack of diversification in its revenue streams. The company's growth trajectory is reflected in its revenue and earnings estimates. The mean revenue estimate is 421,500,000 SEK, while the last actual revenue was 313,346,000 SEK, indicating a potential increase in revenue. The mean EPS estimate is 1.91 SEK, compared to the last actual EPS of -0.72 SEK, suggesting a significant improvement in earnings. These estimates should be monitored to assess the company's future performance. Paxman AB (publ) faces a medium liquidity risk, as indicated by the risk assessment, and a low dilution risk. The company's capital structure includes total liabilities of 47,800,000 SEK and total equity of 136,050,000 SEK, with a debt-to-equity ratio of 0.13. The company's liquidity is further reflected in its current ratio of 2.35, which suggests that it has sufficient current assets to cover its current liabilities. However, the company has a negative net cash position after subtracting total debt, which could impact its liquidity. Recent events and filings for Paxman AB (publ) are not detailed in the provided data. Analysts have provided price targets ranging from 93.00 SEK to 103.00 SEK, with a mean of 98.00 SEK, indicating a positive outlook on the company's stock. The company's performance and strategic initiatives should be closely monitored to understand the factors driving these price targets.

30-day price · PAX+0.95 (+2.0%)
Low$44.80High$52.60Close$48.25As of13 May, 00:00 UTC
Profile
CompanyPaxman AB (publ)
TickerPAX.ST
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. Paxman AB (publ) is a medical equipment and supplies company that generates revenue primarily through the sale of healthcare products and services.

Classification. Paxman AB (publ) is classified under the Healthcare Services & Equipment business sector within the Healthcare economic sector, with a classification confidence of 0.92.

Paxman AB (publ) has a market price of 11.56 SEK and a market capitalization of 269,040,688.96 SEK, indicating a moderate valuation in the healthcare equipment and supplies industry. The company's price-to-earnings ratio of 20.52 and price-to-book ratio of 1.98 suggest that investors are paying a premium for its earnings and book value. The enterprise value to EBITDA ratio of 38.65 and enterprise value to revenue ratio of 4.88 indicate that the company is valued at a high multiple of its earnings and revenue. In terms of profitability, Paxman AB (publ) has a return on equity of 9.63% and a return on assets of 7.13%, which are metrics that reflect the company's ability to generate profits from its equity and assets. The company's operating income of 7,405,000 SEK and net income of 13,108,000 SEK demonstrate its capacity to generate profits from its operations. However, these figures should be compared to the industry median to determine if they are above or below average. Paxman AB (publ) has a revenue of 58,620,000 SEK, and there is no specific information provided about its segments or geographic exposure. The company's revenue concentration is not detailed, but it is important to consider the potential risks associated with a lack of diversification in its revenue streams. The company's growth trajectory is reflected in its revenue and earnings estimates. The mean revenue estimate is 421,500,000 SEK, while the last actual revenue was 313,346,000 SEK, indicating a potential increase in revenue. The mean EPS estimate is 1.91 SEK, compared to the last actual EPS of -0.72 SEK, suggesting a significant improvement in earnings. These estimates should be monitored to assess the company's future performance. Paxman AB (publ) faces a medium liquidity risk, as indicated by the risk assessment, and a low dilution risk. The company's capital structure includes total liabilities of 47,800,000 SEK and total equity of 136,050,000 SEK, with a debt-to-equity ratio of 0.13. The company's liquidity is further reflected in its current ratio of 2.35, which suggests that it has sufficient current assets to cover its current liabilities. However, the company has a negative net cash position after subtracting total debt, which could impact its liquidity. Recent events and filings for Paxman AB (publ) are not detailed in the provided data. Analysts have provided price targets ranging from 93.00 SEK to 103.00 SEK, with a mean of 98.00 SEK, indicating a positive outlook on the company's stock. The company's performance and strategic initiatives should be closely monitored to understand the factors driving these price targets.
Key takeaways
  • Paxman AB (publ) has a market price of 11.56 SEK and a market capitalization of 269,040,688.96 SEK, indicating a moderate valuation in the healthcare equipment and supplies industry.
  • The company's price-to-earnings ratio of 20.52 and price-to-book ratio of 1.98 suggest that investors are paying a premium for its earnings and book value.
  • Paxman AB (publ) has a return on equity of 9.63% and a return on assets of 7.13%, which are metrics that reflect the company's ability to generate profits from its equity and assets.
  • The company's capital structure includes total liabilities of 47,800,000 SEK and total equity of 136,050,000 SEK, with a debt-to-equity ratio of 0.13.
  • Analysts have provided price targets ranging from 93.00 SEK to 103.00 SEK, with a mean of 98.00 SEK, indicating a positive outlook on the company's stock.
  • # RATIONALES
  • {
  • "margin_outlook_rationale": "The company's operating income and net income indicate a positive margin outlook, driven by its ability to generate profits from its operations.",
Financial snapshot
PeriodHA-latest
CurrencySEK
Revenue$58.6M
Gross profit$40.5M
Operating income$7.4M
Net income$13.1M
R&D
SG&A
D&A
SBC
Operating cash flow$10.1M
CapEx-$7.9M
Free cash flow$9.5M
Total assets$183.8M
Total liabilities$47.8M
Total equity$136.1M
Cash & equivalents
Long-term debt$17.2M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$96.2M-$10.6M-$12.8M-$23.1M
FY-3$145.9M-$1.2M-$10.3M-$28.6M
FY-2$210.1M$12.6M$8.3M$2.1M
FY-1$253.0M$33.5M$40.2M$39.2M
FY0$313.3M$4.1M-$16.7M-$16.0M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$166.3M$125.8M
FY-3$174.0M$114.2M
FY-2$167.1M$122.6M
FY-1$227.2M$164.0M
FY0$479.1M$405.2M
PeriodOCFCapExFCFSBC
FY-4-$4.1M-$23.8M-$23.1M
FY-3$2.7M-$35.7M-$28.6M
FY-2$15.6M-$25.3M$2.1M
FY-1$32.6M-$17.2M$39.2M
FY0$7.4M-$23.5M-$16.0M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$58.6M$7.4M$13.1M$9.5M
FQ-6$63.4M$10.6M$9.8M$9.6M
FQ-5$64.8M$8.5M$5.0M$5.7M
FQ-4$66.2M$7.0M$12.3M$14.4M
FQ-3$67.1M$6.2M-$5.5M-$5.5M
FQ-2$74.9M$576.0k-$3.1M-$3.6M
FQ-1$86.9M$951.0k$1.3M$2.6M
FQ0$84.4M-$3.5M-$9.2M-$9.5M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$183.8M$136.1M
FQ-6$190.3M$145.9M
FQ-5$207.8M$150.8M
FQ-4$227.2M$164.0M
FQ-3$321.2M$276.0M
FQ-2$498.9M$425.8M
FQ-1$487.6M$427.8M
FQ0$479.1M$405.2M
PeriodOCFCapExFCFSBC
FQ-7$10.1M-$7.9M$9.5M
FQ-6$22.3M-$12.3M$9.6M
FQ-5$23.4M-$14.9M$5.7M
FQ-4$32.6M-$17.2M$14.4M
FQ-3$6.2M-$4.2M-$5.5M
FQ-2$6.6M-$8.9M-$3.6M
FQ-1$604.0k-$14.4M$2.6M
FQ0$7.4M-$23.5M-$9.5M
Valuation
Market price$11.56
Market cap$269.0M
Enterprise value$286.2M
P/E20.5
Reported non-GAAP P/E
EV/Revenue4.9
EV/Op income38.6
EV/OCF28.3
P/B2.0
P/Tangible book2.0
Tangible book$136.1M
Net cash-$17.2M
Current ratio2.4
Debt/Equity0.1
ROA7.1%
ROE9.6%
Cash conversion77.0%
CapEx/Revenue-13.5%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 369 companies
MetricPAXActivity
Op margin12.6%3.9% medp25 -31.3% · p75 14.4%above median
Net margin22.4%2.4% medp25 -30.5% · p75 11.1%top quartile
Gross margin69.1%46.7% medp25 28.2% · p75 63.1%top quartile
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-13.5%-4.8% medp25 -11.6% · p75 -2.4%bottom quartile
Debt / equity13.0%17.9% medp25 2.7% · p75 52.2%below median
Observations
IR observations
Mean price target98.00 SEK
Median price target98.00 SEK
High price target103.00 SEK
Low price target93.00 SEK
Mean EPS estimate1.91 SEK
Last actual EPS-0.72 SEK
Mean revenue estimate421,500,000 SEK
Last actual revenue313,346,000 SEK
Mean EBIT estimate41,000,000 SEK
Social pillar8.02 (0-100)
Governance pillar5.72 (0-100)
ESG controversies score100.00 (0-100, higher = fewer controversies)
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-16 14:34 UTC#9750e25f
Market quoteclose SEK 12.33 · shares 0.02B diluted
no public URL
2026-05-16 14:34 UTC#71fd7272
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 22:22 UTCJob: d8abc347